US4602003A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
Assignee: Medical Research Foundation of Oregon
•
Filing: 1982-05-17
•
Granted: 1986-07-22
•
Expires: 2002-05-17
Abstract
Abstract Synthetic sapogenin and sterol compounds, administered orally to warm-blooded animals, inhibit the absorption of cholesterol and are useful in the treatment of hypercholesterolemia. Particular compounds suitable for such purposes include glycosides with spirostane, spirostene, or cholesterol aglycones, and esters of spirostanes, spirostenes and cholesterol.
Inventors
- 👤 M. Rene Malinow
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 01:10
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; C; C07; C07J; C07J71/00; C07J71/0005
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
45 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of a nontoxic, substantially pure, synthetic, glycosidic compound selected from the group consisting of glycosides having tigogenin aglycones.
Claim 2
Independent Claim
45 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of a nontoxic, substantially pure, synthetic, glycosidic compound selected from the group consisting of glycosides having tigogenin aglycones.
Claim 3
Dependent Claim
11 words
The method of claim 1 wherein the glycoside is a glucoside.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein the glycoside is a glucose-tigogenin.
Claim 5
Dependent Claim
11 words
The method of claim 2 wherein the glycoside is a cellobiose-tigogenin.
Claim 6
Dependent Claim
11 words
The method of claim 4 wherein the glycoside is a β-cellobiose-tigogenin.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein the glycoside is administered orally.
Claim 8
Independent Claim
32 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering an effective amount of a nontoxic cholesterol glycoside to the subject.
Claim 9
Independent Claim
32 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering an effective amount of a nontoxic cholesterol glycoside to the subject.
Claim 10
Independent Claim
30 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of a glucose-cholesterol.
Claim 11
Independent Claim
30 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of a glucose-cholesterol.
Claim 12
Dependent Claim
11 words
The method of claim 8 wherein the glucose-cholesterol is a cellobiose-cholesterol.
Claim 13
Dependent Claim
11 words
The method of claim 9 wherein the glucose-cholesterol is a β-cellobiose-cholesterol.
Claim 14
Dependent Claim
12 words
The method of claim 7 wherein the cholesterol glycoside is administered orally.
Claim 15
Dependent Claim
21 words
The method of claim 1 wherein the glycoside consists of a carbohydrate bonded to the aglycone by a β-oriented glycosidic bond.
Claim 16
Independent Claim
43 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of an ester selected from the group consisting of diosgenin maleate, tigogenin maleate, and mixtures thereof.
Claim 17
Independent Claim
43 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of an ester selected from the group consisting of diosgenin maleate, tigogenin maleate, and mixtures thereof.
Claim 18
Dependent Claim
11 words
The method of claim 8 wherein the glucose-cholesterol is administered orally.
Claim 19
Independent Claim
30 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of cholesterol maleate.
Claim 20
Independent Claim
30 words
A method of treating a human or other warm-blooded animal subject to reduce digestive absorption of cholesterol, the method comprising administering to the subject an effective amount of cholesterol maleate.
References Cited (Backward Citations)
US3160626A
Cited
US3303187A
Cited
US3992315A
Cited
US4188379A
Cited
US4198401A
Cited
FR2425859A1
Cited
US4254111A
Cited
US4265886A
Cited
US4260603A
Cited
US4242502A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-07-21 | 1990-01-20 | 1990-07-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-07-21 | 1994-01-20 | 1994-07-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-07-21 | 1998-01-20 | 1998-07-22 | $7700.00 | Window Closed / Lapsed |